These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Zhang DL; Liu J; Liu S; Zhang Y; Liu WH Ren Fail; 2010; 32(8):935-40. PubMed ID: 20722560 [TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethyl arginine levels in chronic hemodialysis patients. Cifci A; Inal S; Kaya C Turk J Med Sci; 2014; 44(4):606-10. PubMed ID: 25551930 [TBL] [Abstract][Full Text] [Related]
6. Biphasic changes in nitric oxide generation in hemodialyzed patients with end-stage renal disease treated with recombinant human erythropoietin. Kang ES; Wang YB; Cardenas R; Tevlin MT; Mishra S; Acchiardo SR Am J Med Sci; 2000 Mar; 319(3):149-57. PubMed ID: 10746825 [TBL] [Abstract][Full Text] [Related]
7. Plasma asymmetric dimethylarginine, symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with chronic kidney disease and hypertension. Jepson RE; Syme HM; Vallance C; Elliott J J Vet Intern Med; 2008; 22(2):317-24. PubMed ID: 18371026 [TBL] [Abstract][Full Text] [Related]
8. Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease. Kang ES; Miles DE; Tevlin MT; Cates TB; Acchiardo SR Am J Med Sci; 2001 Feb; 321(2):113-23. PubMed ID: 11217813 [TBL] [Abstract][Full Text] [Related]
9. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Uzun H; Konukoglu D; Besler M; Erdenen F; Sezgin C; Muderrisoglu C Clin Invest Med; 2008; 31(1):E1-7. PubMed ID: 18312743 [TBL] [Abstract][Full Text] [Related]
11. Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Kang ES; Tevlin MT; Wang YB; Chiang TM; Cardenas R; Myers LK; Acchiardo SR Am J Med Sci; 1999 Jan; 317(1):9-21. PubMed ID: 9892267 [TBL] [Abstract][Full Text] [Related]
12. Serum apelin and ADMA levels in type 2 diabetics with and without vascular complications. KarakoƧ A; Sahin A; Polat ES; Aliyev E; Yildirim A; Bakan N; Dokumacioglu E Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S106-9. PubMed ID: 27083312 [TBL] [Abstract][Full Text] [Related]
13. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. El-Shehaby AM; El-Khatib MM; Battah AA; Roshdy AR Scand J Clin Lab Invest; 2010 Oct; 70(6):421-7. PubMed ID: 20645679 [TBL] [Abstract][Full Text] [Related]
14. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Thaha M; Widodo ; Pranawa W; Yogiantoro M; Tomino Y Clin Nephrol; 2008 Jan; 69(1):24-32. PubMed ID: 18226399 [TBL] [Abstract][Full Text] [Related]
15. Dimethylarginine levels and nutritional status in hemodialysis patients. Cupisti A; Saba A; D'Alessandro C; Meola M; Panicucci E; Panichi V; Raffaelli A; Barsotti G J Nephrol; 2009; 22(5):623-9. PubMed ID: 19809995 [TBL] [Abstract][Full Text] [Related]
16. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. Osanai T; Fujiwara N; Saitoh M; Sasaki S; Tomita H; Nakamura M; Osawa H; Yamabe H; Okumura K Blood Purif; 2002; 20(5):466-8. PubMed ID: 12207094 [TBL] [Abstract][Full Text] [Related]
17. Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. Csiky B; Sulyok E; Lakatos O; Wittmann I; Martens-Lobenhoffer J; Bode-Boger SM Nephron Clin Pract; 2008; 108(2):c127-34. PubMed ID: 18230915 [TBL] [Abstract][Full Text] [Related]
18. The prediction roles of asymmetric dimethyl-arginine, adiponectin and apelin for macroangiopathy in patients with impaired glucose regulation. Huang S; Zou D; Peng W; Jiang X; Shao K; Xia L; Tang Y Ann Endocrinol (Paris); 2016 Dec; 77(6):633-640. PubMed ID: 27641081 [TBL] [Abstract][Full Text] [Related]